ClinicalTrials.gg
RecruitingNCT05935358NuPOWERUpdated Nov 16, 2026

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

A Phase 4 interventional study of Nuwiq in Severe Hemophilia A, sponsored by Octapharma. Recruiting at 18 sites in 11 countries. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Octapharma · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.
Updated Nov 16, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
12 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies in Hemophilia A by Octapharma — 3 open to participants now, 3 under way, none of them phase 3. Hemophilia A · Octapharma.

Planned enrollment
8th of 12
28 · median 34
Started
2023
the only one that year
Phase 4
2 of 15
2 open now
Registered
14th of 15
by date

Among the 15 studies in Hemophilia A by Octapharma, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 4, and was the 14th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

3 of the 15 studies in Hemophilia A by Octapharma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hemophilia A by Octapharma, or all of them as a file.
02

Study summary

Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis

Read the detailed description

Patients with severe haemophilia A receiving emicizumab will often need concomitant FVIII to provide haemostatic cover during major surgery. This prospective, open-label, uncontrolled, single-arm, multinational, multicentre study aims to evaluate the overall perioperative haemostatic efficacy of Nuwiq, a recombinant factor VIII, in combination with emicizumab prophylaxis in male patients over 12 with severe haemophilia A undergoing major surgery.

03

Conditions studied

  • Severe Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe haemophilia A (FVIII activity [FVIII:C] \<1%) according to medical history
  • Male patients at least 12 years of age
  • Previous treatment with any FVIII product(s) for at least 150 exposure days
  • On regular prophylaxis with emicizumab for at least 1 month prior to a scheduled major elective surgery requiring FVIII treatment
  • Freely given written of the patient, or parent/legal representative where applicable, obtained in accordance with local regulations

Exclusion criteria

Exclusion Criteria:

  • Coagulation disorder other than haemophilia A
  • Present or past FVIII inhibitor (≥0.6 Bethesda units [BU]/mL) according to medical history
  • Severe liver or kidney disease ( [ALT] and/or aspartate aminotransferase [AST] levels >5 times the ; or creatinine >120 μmol/L)
  • Known to Nuwiq's active substance or its (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188)
  • Already had surgery in this study
  • Current participation in another interventional clinical trial
  • Treatment with any medicinal product (IMP) within 30 days prior to screening visit
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Nuwiq

    All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL.

    Drug: Nuwiq

Interventions

  • DrugNuwiq

    Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).

06

What researchers measure

Primary outcomes

  1. Overall haemostatic efficacy

    Overall haemostatic efficacy of treatment measured as binary "success" or "failure". The overall perioperative haemostatic efficacy of Nuwiq will be adjudicated by an Independent Data Monitoring Committee (IDMC) and determined using a composite assessment algorithm that considers the surgeon's assessment of intraoperative haemostatic efficacy and the investigator's assessment of postoperative haemostatic efficacy to classify the overall haemostatic efficacy as success or failure.

    Time frame: During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure

Secondary outcomes

  1. Intraoperative haemostatic efficacy

    Assessment of intraoperative haemostatic efficacy of Nuwiq using a 4-point ordinal scale: Excellent: Intraoperative blood loss was lower than or equal to the average expected blood loss for the type of procedure performed in a patient with normal haemostasis and of the same sex, age, and stature Good: Intraoperative blood loss was higher than the average expected blood loss but lower or equal to the maximal expected blood loss for the type of procedure in a patient with normal haemostasis. Moderate: Intraoperative blood loss was higher than the maximum expected blood loss for the type of procedure performed in a patient with normal haemostasis, but haemostasis was controlled. None: Haemostasis was uncontrolled, necessitating a change in the clotting factor replacement regimen.

    Time frame: During surgery: From first skin incision to last suture

  2. Postoperative haemostatic efficacy

    Assessment of postoperative haemostatic efficacy of Nuwiq using a 4-point ordinal scale: Excellent: No postoperative bleeding or oozing that was not due to complications of surgery. All postoperative bleeding (due to complications of surgery) was controlled with Nuwiq as anticipated for the type of procedure. Good: No postoperative bleeding or oozing that was not due to complications of surgery. Control of postoperative bleeding due to complications of surgery required increased dosing with Nuwiq or additional injections not originally anticipated for the type of procedure. Moderate: Some postoperative bleeding and oozing that was not due to complications of surgery. Control of postoperative bleeding required increased dosing with Nuwiq or additional injections not originally anticipated for the type of procedure. None: Extensive uncontrolled postoperative bleeding and oozing.

    Time frame: From end of surgery until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure

  3. Blood product transfusion levels

    The number of allogeneic blood products (red blood cells, platelets, and other blood products) transfused

    Time frame: From day of surgery until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure

  4. FVIII plasma levels

    Perioperative plasma levels

    Time frame: ≤30 minutes before and 15-30 minutes after Nuwiq injection

  5. Thrombin generation

    Perioperative thrombin generation

    Time frame: ≤30 minutes before and 15-30 minutes after Nuwiq injection

  6. Perioperative haemostatic efficacy per World Federation of Hemophilia (WFH) criteria

    Assessed on WFH recommended 4-point scale: Excellent: Intra and post-operative blood loss, with blood component transfusions, similar to non-haemophilic patients. No additional FVIII/bypassing agents Good: Intra/ post-operative blood loss slightly increased over expectation for non-haemophilic patient but clinically insignificant. Blood component transfusions similar to non-haemophilic patient. No additional FVIII/bypassing agents Fair: Intra/ post-operative blood loss increased over expectation for non-haemophilic patients, and additional treatment needed. Extra dose of FVIII/bypassing agents needed or increased blood component of anticipated transfusion requirement Poor: Significant intra- or post-operative blood loss substantially increased over non-haemophilic patient, requires haemophilia-related medical intervention. Unexpected hypotension, transfer to ICU due to bleeding or substantially increased blood component of anticipated transfusion requirement

    Time frame: Perioperative

  7. Thrombotic events

    Incidence of thrombotic events during the study

    Time frame: From start of first Nuwiq injection to 30 ± 3 days following the surgical procedure or until day of discharge, whichever is later

  8. FVIII inhibitor formation

    Incidence of FVIII inhibitor formation

    Time frame: From start of first Nuwiq injection to 30 ± 3 days following the surgical procedure or until day of discharge, whichever is later

  9. Adverse events

    Incidence of adverse events recorded during the full study period

    Time frame: From start of first Nuwiq injection to 30 ± 3 days following the surgical procedure or until day of discharge, whichever is later

07

Study locations

11 of 18 sites recruiting
08

References and documents

Publications

  • Srivastava A, Kanny A, Langer F, Kubicek-Hofmann C, Alvarez Roman MT, Nunez Vazquez R, Boban A, Dejanova-Ilijevska V, Miljic P, Garcia J, Halimeh S, Drillaud N, Valentin JB, Mancuso ME, Castaman G, Santoro RC, Lehtinen AE, Abraham A, Hashimoto M, Knaub S. NuPOWER (Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis): protocol for an open-label, single-arm, multicentre study. BMJ Open. 2025 Oct 28;15(10):e102657. doi: 10.1136/bmjopen-2025-102657. PubMed 41151952 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's planned 37 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2023
First posted
Jul 7, 2023
StartActual
Nov 28, 2023
Primary completionEst.
Dec 2026was Aug 2026
CompletionEst.
Dec 2026was Sep 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites changed recruiting status (6 now terminated, 1 now completed, …)
Show 8 sites
  • CHRU de Tours · Tours, FranceRecruiting→Terminated
  • Vivantes Klinikum im Friedrichshein (KFH) · Berlin, GermanyRecruiting→Terminated
  • Christian Medical College Vellore · Vellore, IndiaRecruiting→Completed
  • Azienda Ospedaliera Pugliese Ciaccio · Catanzaro, ItalyRecruiting→Terminated
  • Azienda Ospedaliero Universitaria Careggi - Centro Emofilia · Florence, ItalyRecruiting→Terminated
  • Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital · Milan, ItalyRecruiting→Terminated
  • Hospital Universitario Virgen del Rocio · Seville, SpainRecruiting→Terminated
  • St. James's University Hospital · Leeds, United KingdomNot yet recruiting→Recruiting
Nov 16, 2026
Primary completion
Aug 2026→Dec 2026
Nov 16, 2026
Study completion
Sep 2026→Dec 2026
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    8 sites changed recruiting status (6 now terminated, 1 now completed, …)
    Show 8 sites
    • CHRU de Tours · Tours, FranceRecruiting→Terminated
    • Vivantes Klinikum im Friedrichshein (KFH) · Berlin, GermanyRecruiting→Terminated
    • Christian Medical College Vellore · Vellore, IndiaRecruiting→Completed
    • Azienda Ospedaliera Pugliese Ciaccio · Catanzaro, ItalyRecruiting→Terminated
    • Azienda Ospedaliero Universitaria Careggi - Centro Emofilia · Florence, ItalyRecruiting→Terminated
    • Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital · Milan, ItalyRecruiting→Terminated
    • Hospital Universitario Virgen del Rocio · Seville, SpainRecruiting→Terminated
    • St. James's University Hospital · Leeds, United KingdomNot yet recruiting→Recruiting
    Primary completion Aug 2026→Dec 2026
    Study completion Sep 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05935358
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
Jul 7, 2023
Start date
Nov 28, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Sigurd Knaub, PhD
Contact
Sigurd.Knaub@octapharma.com
+41 554512141
Shveta Gupta, MD
principal investigator · Arnold Palmer Hospital for Children

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simoctocog alfa (Nuwiq)

Start the discussion